APO RESEARCH · REPORT
Anti-tumor Drug
Anti-tumor drugs are for the treatment of cancer diseases. In recent years, the development of molecular oncology and molecular pharmacology has gradually clarified the nature of the tumor. The invention and application of advanced technologies such as large-scale rapid screening, combinatorial chemistry and genetic engineering have accelerated the process of drug development. The research and development of anti-tumor drugs have been into a new era.
Product & engineering
Understand the product.
Anti-tumor drugs are for the treatment of cancer diseases. In recent years, the development of molecular oncology and molecular pharmacology has gradually clarified the nature of the tumor. The invention and application of advanced technologies such as large-scale rapid screening, combinatorial chemistry and genetic engineering have accelerated the process of drug development. The research and development of anti-tumor drugs have been into a new era.
Selected research
Industry Growth & Trends
Global Anti-tumor Drug Industry Growth and Trends Forecast to 2032
Market perspective
Anti-tumor drugs are for the treatment of cancer diseases. In recent years, the development of molecular oncology and molecular pharmacology has gradually clarified the nature of the tumor. The invention and application of advanced technologies such as large-scale rapid screening, combinatorial chemistry and genetic engineering have accelerated the process of drug development. The research and development of anti-tumor drugs have been into a new era.
According to APO Research, the global Anti-tumor Drug market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.
Report Scope
Read the full market overview
This report provides a structured, data-driven view of the global Anti-tumor Drug market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.
The Anti-tumor Drug market size, estimates, and forecasts are presented in terms of revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Anti-tumor Drug market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Anti-tumor Drug.
Key Companies & Market Share Insights
This section analyzes the strategies and performance of leading companies in the global Anti-tumor Drug market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue and gross margin data by manufacturer for 2021-2026, enabling benchmarking of scale, profitability, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.
Anti-tumor Drug Market by Company
Roche
Novartis
Celgene
Bristol-Myers Squibb
Amgen
Johnson & Johnson
Pfizer
Takeda
Eli Lilly
AstraZeneca
Astellas
Merck & Co
Sanofi
Bayer
Biogen Idec
Eisai
Teva
Otsuka
Anti-tumor Drug Segment by Type
Cytotoxic Drugs
Non-cytotoxic Drugs
Anti-tumor Drug Segment by Application
Alkylating Agents
Anti-Metabolism Drugs
Platinum Antineoplastic Agents
Anthracycline Antitumor Drugs
Microtubule Stabilizer
Endocrine Therapy Drugs
Immunotherapy Drugs
Gene Therapy Drugs
Targeted Antineoplastic Drugs
Anti-tumor Drug Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Anti-tumor Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Anti-tumor Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Anti-tumor Drug.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2021-2025, 2026-2031). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 3: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 4: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 5: Detailed analysis of Anti-tumor Drug companies' competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, revenue by country.
Chapter 12: Concluding Insights of the report
More report detail
Tables and figures
Scope & coverage.
Types
- Cytotoxic Drugs
- Non-cytotoxic Drugs
Applications
- Alkylating Agents
- Anti-Metabolism Drugs
- Platinum Antineoplastic Agents
- Anthracycline Antitumor Drugs
- Microtubule Stabilizer
- Endocrine Therapy Drugs
- Immunotherapy Drugs
- Gene Therapy Drugs
- Targeted Antineoplastic Drugs
Companies covered
- Roche
- Novartis
- Celgene
- Bristol-Myers Squibb
- Amgen
- Johnson & Johnson
- Pfizer
- Takeda
- Eli Lilly
- AstraZeneca
- Astellas
- Merck & Co
- Sanofi
- Bayer
- Biogen Idec
- Eisai
- Teva
- Otsuka
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Market Growth Prospects
- 1.3 Global Anti-tumor Drug Market Size Overview by Region 2021 VS 2025 VS 2032
- 1.4 Global Anti-tumor Drug Market Size by Region (2021-2032)
- 1.4.1 Global Anti-tumor Drug Market Size by Region (2021-2026)
- 1.4.2 Global Anti-tumor Drug Market Size by Region (2027-2032)
- 1.5 Key Regions Anti-tumor Drug Market Size (2021-2032)
- 1.5.1 North America Anti-tumor Drug Market Size Growth Rate (2021-2032)
- 1.5.2 Europe Anti-tumor Drug Market Size Growth Rate (2021-2032)
- 1.5.3 Asia-Pacific Anti-tumor Drug Market Size Growth Rate (2021-2032)
- 1.5.4 South America Anti-tumor Drug Market Size Growth Rate (2021-2032)
- 1.5.5 Middle East & Africa Anti-tumor Drug Market Size Growth Rate (2021-2032)
2 Anti-tumor Drug Market by Type
- 2.1 Type Introduction
- 2.1.1 Cytotoxic Drugs
- 2.1.2 Non-cytotoxic Drugs
- 2.2 Global Anti-tumor Drug Market Size by Type
- 2.2.1 Global Anti-tumor Drug Market Size Overview by Type (2021-2032)
- 2.2.2 Global Anti-tumor Drug Historic Market Size Review by Type (2021-2026)
- 2.2.3 Global Anti-tumor Drug Market Size Forecasted by Type (2027-2032)
- 2.3 Global Anti-tumor Drug Market Size by Regions
- 2.3.1 North America Anti-tumor Drug Market Size Breakdown by Type (2021-2026)
- 2.3.2 Europe Anti-tumor Drug Market Size Breakdown by Type (2021-2026)
- 2.3.3 Asia-Pacific Anti-tumor Drug Market Size Breakdown by Type (2021-2026)
- 2.3.4 South America Anti-tumor Drug Market Size Breakdown by Type (2021-2026)
- 2.3.5 Middle East and Africa Anti-tumor Drug Market Size Breakdown by Type (2021-2026)
3 Anti-tumor Drug Market by Application
- 3.1 Type Introduction
- 3.1.1 Alkylating Agents
- 3.1.2 Anti-Metabolism Drugs
- 3.1.3 Platinum Antineoplastic Agents
- 3.1.4 Anthracycline Antitumor Drugs
- 3.1.5 Microtubule Stabilizer
- 3.1.6 Endocrine Therapy Drugs
- 3.1.7 Immunotherapy Drugs
- 3.1.8 Gene Therapy Drugs
- 3.1.9 Targeted Antineoplastic Drugs
- 3.2 Global Anti-tumor Drug Market Size by Application
- 3.2.1 Global Anti-tumor Drug Market Size Overview by Application (2021-2032)
- 3.2.2 Global Anti-tumor Drug Historic Market Size Review by Application (2021-2026)
- 3.2.3 Global Anti-tumor Drug Market Size Forecasted by Application (2027-2032)
- 3.3 Global Anti-tumor Drug Market Size by Regions
- 3.3.1 North America Anti-tumor Drug Market Size Breakdown by Application (2021-2026)
- 3.3.2 Europe Anti-tumor Drug Market Size Breakdown by Application (2021-2026)
- 3.3.3 Asia-Pacific Anti-tumor Drug Market Size Breakdown by Application (2021-2026)
- 3.3.4 South America Anti-tumor Drug Market Size Breakdown by Application (2021-2026)
- 3.3.5 Middle East and Africa Anti-tumor Drug Market Size Breakdown by Application (2021-2026)
4 Global Market Dynamics
- 4.1 Anti-tumor Drug Industry Trends
- 4.2 Anti-tumor Drug Industry Drivers
- 4.3 Anti-tumor Drug Industry Opportunities and Challenges
- 4.4 Anti-tumor Drug Industry Restraints
5 Competitive Insights by Company
- 5.1 Global Top Players by Anti-tumor Drug Revenue (2021-2026)
- 5.2 Global Anti-tumor Drug Industry Company Ranking, 2024 VS 2025 VS 2026
- 5.3 Global Anti-tumor Drug Key Company Headquarters & Area Served
- 5.4 Global Anti-tumor Drug Company, Product Type & Application
- 5.5 Global Anti-tumor Drug Company Commercialization Time
- 5.6 Market Competitive Analysis
- 5.6.1 Global Anti-tumor Drug Market CR5 and HHI
- 5.6.2 Global Top 5 and 10 Anti-tumor Drug Players Market Share by Revenue in 2025
- 5.6.3 2025 Anti-tumor Drug Tier 1, Tier 2, and Tier 3
6 Company Profiles
- 6.1 Roche
- 6.1.1 Roche Company Information
- 6.1.2 Roche Business Overview
- 6.1.3 Roche Anti-tumor Drug Revenue, Global Share and Gross Margin (2021-2026)
- 6.1.4 Roche Anti-tumor Drug Product Portfolio
- 6.1.5 Roche Recent Developments
- 6.2 Novartis
- 6.2.1 Novartis Company Information
- 6.2.2 Novartis Business Overview
- 6.2.3 Novartis Anti-tumor Drug Revenue, Global Share and Gross Margin (2021-2026)
- 6.2.4 Novartis Anti-tumor Drug Product Portfolio
- 6.2.5 Novartis Recent Developments
- 6.3 Celgene
- 6.3.1 Celgene Company Information
- 6.3.2 Celgene Business Overview
- 6.3.3 Celgene Anti-tumor Drug Revenue, Global Share and Gross Margin (2021-2026)
- 6.3.4 Celgene Anti-tumor Drug Product Portfolio
- 6.3.5 Celgene Recent Developments
- 6.4 Bristol-Myers Squibb
- 6.4.1 Bristol-Myers Squibb Company Information
- 6.4.2 Bristol-Myers Squibb Business Overview
- 6.4.3 Bristol-Myers Squibb Anti-tumor Drug Revenue, Global Share and Gross Margin (2021-2026)
- 6.4.4 Bristol-Myers Squibb Anti-tumor Drug Product Portfolio
- 6.4.5 Bristol-Myers Squibb Recent Developments
- 6.5 Amgen
- 6.5.1 Amgen Company Information
- 6.5.2 Amgen Business Overview
- 6.5.3 Amgen Anti-tumor Drug Revenue, Global Share and Gross Margin (2021-2026)
- 6.5.4 Amgen Anti-tumor Drug Product Portfolio
- 6.5.5 Amgen Recent Developments
- 6.6 Johnson & Johnson
- 6.6.1 Johnson & Johnson Company Information
- 6.6.2 Johnson & Johnson Business Overview
- 6.6.3 Johnson & Johnson Anti-tumor Drug Revenue, Global Share and Gross Margin (2021-2026)
- 6.6.4 Johnson & Johnson Anti-tumor Drug Product Portfolio
- 6.6.5 Johnson & Johnson Recent Developments
- 6.7 Pfizer
- 6.7.1 Pfizer Company Information
- 6.7.2 Pfizer Business Overview
- 6.7.3 Pfizer Anti-tumor Drug Revenue, Global Share and Gross Margin (2021-2026)
- 6.7.4 Pfizer Anti-tumor Drug Product Portfolio
- 6.7.5 Pfizer Recent Developments
- 6.8 Takeda
- 6.8.1 Takeda Company Information
- 6.8.2 Takeda Business Overview
- 6.8.3 Takeda Anti-tumor Drug Revenue, Global Share and Gross Margin (2021-2026)
- 6.8.4 Takeda Anti-tumor Drug Product Portfolio
- 6.8.5 Takeda Recent Developments
- 6.9 Eli Lilly
- 6.9.1 Eli Lilly Company Information
- 6.9.2 Eli Lilly Business Overview
- 6.9.3 Eli Lilly Anti-tumor Drug Revenue, Global Share and Gross Margin (2021-2026)
- 6.9.4 Eli Lilly Anti-tumor Drug Product Portfolio
- 6.9.5 Eli Lilly Recent Developments
- 6.10 AstraZeneca
- 6.10.1 AstraZeneca Company Information
- 6.10.2 AstraZeneca Business Overview
- 6.10.3 AstraZeneca Anti-tumor Drug Revenue, Global Share and Gross Margin (2021-2026)
- 6.10.4 AstraZeneca Anti-tumor Drug Product Portfolio
- 6.10.5 AstraZeneca Recent Developments
- 6.11 Astellas
- 6.11.1 Astellas Company Information
- 6.11.2 Astellas Business Overview
- 6.11.3 Astellas Anti-tumor Drug Revenue, Global Share and Gross Margin (2021-2026)
- 6.11.4 Astellas Anti-tumor Drug Product Portfolio
- 6.11.5 Astellas Recent Developments
- 6.12 Merck & Co
- 6.12.1 Merck & Co Company Information
- 6.12.2 Merck & Co Business Overview
- 6.12.3 Merck & Co Anti-tumor Drug Revenue, Global Share and Gross Margin (2021-2026)
- 6.12.4 Merck & Co Anti-tumor Drug Product Portfolio
- 6.12.5 Merck & Co Recent Developments
- 6.13 Sanofi
- 6.13.1 Sanofi Company Information
- 6.13.2 Sanofi Business Overview
- 6.13.3 Sanofi Anti-tumor Drug Revenue, Global Share and Gross Margin (2021-2026)
- 6.13.4 Sanofi Anti-tumor Drug Product Portfolio
- 6.13.5 Sanofi Recent Developments
- 6.14 Bayer
- 6.14.1 Bayer Company Information
- 6.14.2 Bayer Business Overview
- 6.14.3 Bayer Anti-tumor Drug Revenue, Global Share and Gross Margin (2021-2026)
- 6.14.4 Bayer Anti-tumor Drug Product Portfolio
- 6.14.5 Bayer Recent Developments
- 6.15 Biogen Idec
- 6.15.1 Biogen Idec Company Information
- 6.15.2 Biogen Idec Business Overview
- 6.15.3 Biogen Idec Anti-tumor Drug Revenue, Global Share and Gross Margin (2021-2026)
- 6.15.4 Biogen Idec Anti-tumor Drug Product Portfolio
- 6.15.5 Biogen Idec Recent Developments
- 6.16 Eisai
- 6.16.1 Eisai Company Information
- 6.16.2 Eisai Business Overview
- 6.16.3 Eisai Anti-tumor Drug Revenue, Global Share and Gross Margin (2021-2026)
- 6.16.4 Eisai Anti-tumor Drug Product Portfolio
- 6.16.5 Eisai Recent Developments
- 6.17 Teva
- 6.17.1 Teva Company Information
- 6.17.2 Teva Business Overview
- 6.17.3 Teva Anti-tumor Drug Revenue, Global Share and Gross Margin (2021-2026)
- 6.17.4 Teva Anti-tumor Drug Product Portfolio
- 6.17.5 Teva Recent Developments
- 6.18 Otsuka
- 6.18.1 Otsuka Company Information
- 6.18.2 Otsuka Business Overview
- 6.18.3 Otsuka Anti-tumor Drug Revenue, Global Share and Gross Margin (2021-2026)
- 6.18.4 Otsuka Anti-tumor Drug Product Portfolio
- 6.18.5 Otsuka Recent Developments
7 North America
- 7.1 North America Anti-tumor Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 7.2 North America Anti-tumor Drug Market Size by Country (2021-2026)
- 7.3 North America Anti-tumor Drug Market Size Forecast by Country (2027-2032)
8 Europe
- 8.1 Europe Anti-tumor Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 8.2 Europe Anti-tumor Drug Market Size by Country (2021-2026)
- 8.3 Europe Anti-tumor Drug Market Size Forecast by Country (2027-2032)
9 Asia-Pacific
- 9.1 Asia-Pacific Anti-tumor Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 9.2 Asia-Pacific Anti-tumor Drug Market Size by Country (2021-2026)
- 9.3 Asia-Pacific Anti-tumor Drug Market Size Forecast by Country (2027-2032)
10 South America
- 10.1 South America Anti-tumor Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 10.2 South America Anti-tumor Drug Market Size by Country (2021-2026)
- 10.3 South America Anti-tumor Drug Market Size Forecast by Country (2027-2032)
11 Middle East & Africa
- 11.1 Middle East & Africa Anti-tumor Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 11.2 Middle East & Africa Anti-tumor Drug Market Size by Country (2021-2026)
- 11.3 Middle East & Africa Anti-tumor Drug Market Size Forecast by Country (2027-2032)
12 Concluding Insights
13 Appendix
- 13.1 Reasons for Doing This Study
- 13.2 Research Methodology
- 13.3 Research Process
- 13.4 Authors List of This Report
- 13.5 Data Source
- 13.5.1 Secondary Sources
- 13.5.2 Primary Sources
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst